Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.37 |
| ▸ | SNCA | P37840 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12102392 | 0.86 | KDM4E (0.50) | HPGDKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12102484 | 0.80 | S1PR1 (0.33) | S1PR1S1PR3 | |
| SCHEMBL1293378 | 0.76 | S1PR1 (0.55) | S1PR1S1PR3 | |
| SCHEMBL12102477 | 0.74 | GABRA1 (0.33) | — | |
| SCHEMBL12102409 | 0.73 | S1PR1 (0.39) | S1PR1S1PR3 | |
| SCHEMBL12102428 | 0.73 | S1PR1 (0.42) | S1PR1S1PR3CYP2C9 | |
| SCHEMBL12102437 | 0.71 | S1PR1 (0.35) | S1PR1SNCAHPGDKDM4ESMN1; SMN2 | |
| SCHEMBL12102427 | 0.71 | S1PR1 (0.37) | S1PR1 | |
| SCHEMBL12102438 | 0.70 | S1PR1 (0.34) | S1PR1 | |
| SCHEMBL12102475 | 0.67 | MAPT (0.36) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389508-B2 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-20110269738-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269738-A1 | COMPOUNDS | CYP11B2, CYP11B1, GPR119 | S1PR1 1075/4885SNCA 230/4885HPGD 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.